PDCD1 and melanoma: Further clinical testing of anti-PD-1 therapy revealed objective clinical responses in patients with advanced melanoma [65,66,67], non-small-cell lung cancer (NSCLC) [68,69,70], renal cell carcinoma (RCC) [71,72], bladder cancer [73], and Hodgkin’s lymphoma [74].